Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 15/20 | 0.36 |
| ▸ | APOB | P04114 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14778356 | 0.96 | MTTP (0.37) | MTTPAPOBGPR119NTRK1 | |
| SCHEMBL12185538 | 0.95 | MTTP (0.40) | MTTPAPOB | |
| SCHEMBL12185931 | 0.95 | MTTP (0.40) | MTTPAPOB | |
| SCHEMBL14790211 | 0.94 | MAPT (0.33) | MTTPCHRM3 | |
| SCHEMBL2598182 | 0.93 | MTTP (0.37) | MTTP | |
| SCHEMBL2597845 | 0.89 | TP53 (0.32) | MTTP | |
| SCHEMBL14790145 | 0.89 | MTTP (0.38) | MTTPAPOB | |
| SCHEMBL12185492 | 0.89 | MTTP (0.38) | MTTPAPOB | |
| SCHEMBL14790168 | 0.89 | MTTP (0.40) | MTTPAPOB | |
| SCHEMBL14790204 | 0.89 | MAPT (0.36) | MTTPCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571860-A1 | 2-PHENYL BENZOYLAMIDES | Pfizer Inc (US) | 2013-03-27 | — | — | EP | claimed |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | CONN EDWARD LEE (US) | 2013-03-21 | — | — | US | claimed |
| WO-2011145022-A1 | 2-PHENYL BENZOYLAMIDES | PFIZER INC. (US) | 2011-11-24 | — | — | WO | claimed |
| EP-2571860-A1 | 2-PHENYL BENZOYLAMIDES | Pfizer Inc (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | CONN EDWARD LEE (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | CONN EDWARD LEE (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | CONN EDWARD LEE (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2011145022-A1 | 2-PHENYL BENZOYLAMIDES | PFIZER INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | APOB, MTTP, HADHB | MTTP 2/4885APOB 1/4885GPR119 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.